Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 2
1992 1
1994 2
1995 4
1996 4
1997 2
1998 1
1999 1
2000 3
2001 1
2002 1
2003 1
2004 2
2005 1
2006 1
2007 2
2008 1
2009 1
2010 2
2011 3
2012 2
2013 4
2014 1
2018 1
2019 2
2020 4
2021 7
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

57 results
Results by year
Filters applied: . Clear all
Page 1
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Jhaveri KL, et al. Among authors: luoh sw. Ann Oncol. 2019 Nov 1;30(11):1821-1830. doi: 10.1093/annonc/mdz291. Ann Oncol. 2019. PMID: 31504139 Free PMC article. Clinical Trial.
Breast cancer in premenopausal women.
Vetto JT, Luoh SW, Naik A. Vetto JT, et al. Among authors: luoh sw. Curr Probl Surg. 2009 Dec;46(12):944-1004. doi: 10.1067/j.cpsurg.2009.07.002. Curr Probl Surg. 2009. PMID: 19887229 Review. No abstract available.
IL10RB as a key regulator of COVID-19 host susceptibility and severity.
Voloudakis G, Hoffman G, Venkatesh S, Lee KM, Dobrindt K, Vicari JM, Zhang W, Beckmann ND, Jiang S, Hoagland D, Bian J, Gao L, Corvelo A, Cho K, Lee JS, Iyengar SK, Luoh SW, Akbarian S, Striker R, Assimes TL, Schadt EE, Merad M, tenOever BR, Charney AW; Mount Sinai COVID-19 Biobank; VA Million Veteran Program COVID-19 Science Initiative, Brennand KJ, Lynch JA, Fullard JF, Roussos P. Voloudakis G, et al. Among authors: luoh sw. medRxiv. 2021 Jun 2:2021.05.31.21254851. doi: 10.1101/2021.05.31.21254851. Preprint. medRxiv. 2021. PMID: 34100031 Free PMC article.
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Jhaveri KL, et al. Among authors: luoh sw. Ann Oncol. 2021 Aug;32(8):1068. doi: 10.1016/j.annonc.2021.05.797. Epub 2021 Jun 5. Ann Oncol. 2021. PMID: 34099371 Free PMC article. No abstract available.
57 results